The American Diabetes Association 84th Scientific Sessions, held June 21 to 24 in Orlando, Florida, included dozens of abstracts focused on continuous glucose monitor (CGM) use. Read on for a recap of some of these abstracts, focused on the use of CGM technology in type 2 diabetes.
READ MORE: Continuous Glucose Monitoring Resource Center
References
Alshannaq H, Ahmed M, Norman GJ, Simmons D. Cost-effectiveness of real-time CGM vs. self-monitoring of blood glucose in people with type 2 diabetes on intensive insulin therapy in Australia. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1036-P.
Zheng Y, Greenlee MD, Chen K, et al. Experience of using continuous glucose monitor among Chinese Americans with type 2 diabetes. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1017-P.
Nemlekar P, Hannah K, Norman GJ. The combined effect of CGM with antidiabetes medications and the association with improved A1C in people with type 2 diabetes. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1914-LB.
Barua S, Upadhyay DA, Curran M, et al. Estimating optimal CGM wear time for individuals with type 2 diabetes not on insulin. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1907-LB.
Ehrhardt NM, Wright L, Montour L, et al. A randomized trial of real-time continuous glucose monitoring (RT-CGM) with culturally tailored education for Latino patients with type 2 diabetes (DM). Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1930-LB.